No Data
No Data
JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease
Modalis Therapeutics Reports Loss Due to Electronic Fraud Incident
Modalis Therapeutics Reports Positive Foreign Exchange Gains
Modalis Therapeutics Has Received an Orphan Drug Designation From the U.S. Food and Drug Administration for MDL-101, a Treatment for Congenital Muscular Dystrophy Type 1A (LAMA2-CMD).
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
Modalis to Present Epigenome Editing Data at Genome Editing Summit
No Data